Solriamfetol in Binge Eating Disorder

Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.

"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."